Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.

1 , 3–5 Most importantly, four different long-acting GLP-1RAs (liraglutide, albiglutide, semaglutide and dulaglutide) have been found to the reduce risk of future major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction and stroke) in patients with T2D, with the other long-acting GLP-1RAs, exenatide once-weekly (exeOW) showing a trend towards reduction in MACE combined with a nominally significant reduction in overall mortality. 6–9 When combined together in a meta-analyses, cardiovascular outcome trials on GLP-1RAs have showed efficacy in reducing occurrence of cardiovascular and renal outcomes (progression of albuminuria), and of overall mortality. 10 The outstanding results on cardio-rena

also in 7,732 other papers